PL356987A1 - Drospirenon do hormonalnej terapii zastępczej - Google Patents

Drospirenon do hormonalnej terapii zastępczej

Info

Publication number
PL356987A1
PL356987A1 PL01356987A PL35698701A PL356987A1 PL 356987 A1 PL356987 A1 PL 356987A1 PL 01356987 A PL01356987 A PL 01356987A PL 35698701 A PL35698701 A PL 35698701A PL 356987 A1 PL356987 A1 PL 356987A1
Authority
PL
Poland
Prior art keywords
drospirenone
composition
replacement therapy
hormone replacement
further embodiment
Prior art date
Application number
PL01356987A
Other languages
English (en)
Other versions
PL201878B1 (pl
Inventor
Wolfgang Heil
Jurgen Hilmann
Ralph Lipp
Rolf Schurmann
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL356987(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of PL356987A1 publication Critical patent/PL356987A1/pl
Publication of PL201878B1 publication Critical patent/PL201878B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL356987A 2000-01-18 2001-01-18 Kompozycja farmaceutyczna w doustnej postaci dawkowania. zawierająca estrogen i drospirenon, zastosowanie kompozycji i preparat farmaceutyczny PL201878B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18
PCT/IB2001/000041 WO2001052857A1 (en) 2000-01-18 2001-01-18 Drospirenone for hormone replacement therapy

Publications (2)

Publication Number Publication Date
PL356987A1 true PL356987A1 (pl) 2004-07-12
PL201878B1 PL201878B1 (pl) 2009-05-29

Family

ID=26071749

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356987A PL201878B1 (pl) 2000-01-18 2001-01-18 Kompozycja farmaceutyczna w doustnej postaci dawkowania. zawierająca estrogen i drospirenon, zastosowanie kompozycji i preparat farmaceutyczny

Country Status (30)

Country Link
EP (2) EP1257280B1 (pl)
JP (2) JP5128743B2 (pl)
KR (2) KR100747965B1 (pl)
CN (2) CN1395488A (pl)
AT (2) ATE305789T1 (pl)
AU (3) AU2541301A (pl)
BG (1) BG65849B1 (pl)
BR (1) BR0107683A (pl)
CA (1) CA2394165C (pl)
CY (1) CY1109567T1 (pl)
CZ (1) CZ20022411A3 (pl)
DE (2) DE60139907D1 (pl)
DK (2) DK1257280T3 (pl)
EE (1) EE05533B1 (pl)
ES (2) ES2332226T3 (pl)
HK (2) HK1047248B (pl)
HU (1) HUP0204291A3 (pl)
IL (3) IL150775A0 (pl)
ME (1) ME00292B (pl)
MX (1) MXPA02006613A (pl)
NO (1) NO335570B1 (pl)
NZ (1) NZ520630A (pl)
PL (1) PL201878B1 (pl)
PT (1) PT1611892E (pl)
RS (1) RS52149B (pl)
RU (2) RU2275198C2 (pl)
SI (2) SI1611892T1 (pl)
SK (2) SK287719B6 (pl)
WO (1) WO2001052857A1 (pl)
ZA (2) ZA200206551B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101019361B1 (ko) * 1999-08-31 2011-03-07 바이엘 쉐링 파마 악티엔게젤샤프트 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
JP2004521951A (ja) 2001-07-13 2004-07-22 シエーリング アクチエンゲゼルシャフト Ｈｒｔのためのドロスピレノン及びエストロゲンスルファメートの組み合わせ
JP2005519961A (ja) * 2002-03-11 2005-07-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法
AU2003239162A1 (en) * 2002-04-26 2003-11-10 Schering Ag Treatment of hypertension in women receiving hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
ES2338781T3 (es) * 2002-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Uso de la drospirenona para el tratamiento de una hipertension.
KR20060130723A (ko) * 2004-03-10 2006-12-19 쉐링 악티엔게젤샤프트 분자 분산된 드로스피레논을 포함하는 조성물
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20090181075A1 (en) * 2005-07-15 2009-07-16 Gordon Ryan D Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
US20130137664A1 (en) 2010-04-15 2013-05-30 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
WO2011128337A2 (en) * 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Low-dosed solid oral dosage forms for hrt
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2013064620A1 (de) 2011-11-04 2013-05-10 Bayer Pharma Aktiengesellschaft 18-METHYL-6,7-METHYLEN-3-OXO-17-PREGN-4-EN-21,17β-CARBOLACTONE, PHARMAZEUTISCHE PRÄPARATE ENTHALTEND DIE GENANNTEN VERBINDUNGEN UND DEREN ANWENDUNG BEI DER THERAPIE DER ENDOMETRIOSE
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
EP3701944B1 (en) 2015-06-18 2021-12-08 Estetra SRL Orodispersible dosage unit containing an estetrol component
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
US11253498B2 (en) 2017-06-01 2022-02-22 Nexyon Biotech Co., Ltd. Pharmaceutical composition for treatment of bone-related disease
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
JP2000515890A (ja) * 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
KR101019361B1 (ko) * 1999-08-31 2011-03-07 바이엘 쉐링 파마 악티엔게젤샤프트 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합

Also Published As

Publication number Publication date
DE60139907D1 (de) 2009-10-22
CZ20022411A3 (cs) 2003-02-12
DK1611892T3 (da) 2009-11-02
JP2009120615A (ja) 2009-06-04
EE05533B1 (et) 2012-04-16
DK1257280T3 (da) 2005-12-12
ES2332226T3 (es) 2010-01-29
ATE442147T1 (de) 2009-09-15
AU2001225413B2 (en) 2005-06-23
BG106915A (bg) 2003-04-30
IL191131A0 (en) 2008-11-03
IL150775A0 (en) 2003-02-12
ES2247054T3 (es) 2006-03-01
NO20022966D0 (no) 2002-06-20
CN101934078A (zh) 2011-01-05
CN1395488A (zh) 2003-02-05
EP1257280B1 (en) 2005-10-05
RU2002122113A (ru) 2004-03-10
AU2541301A (en) 2001-07-31
KR100747965B1 (ko) 2007-08-08
JP2003520239A (ja) 2003-07-02
CY1109567T1 (el) 2014-08-13
SK10322002A3 (sk) 2003-03-04
HK1047248B (zh) 2005-12-30
IL191131A (en) 2010-12-30
RU2005140938A (ru) 2007-07-10
HUP0204291A2 (hu) 2003-04-28
BR0107683A (pt) 2002-11-12
NO20022966L (no) 2002-09-18
JP5563227B2 (ja) 2014-07-30
SK288129B6 (sk) 2013-10-02
HUP0204291A3 (en) 2003-05-28
BG65849B1 (bg) 2010-03-31
MXPA02006613A (es) 2003-10-15
SI1257280T1 (sl) 2006-02-28
EP1611892B1 (en) 2009-09-09
DE60113809D1 (de) 2006-02-16
HK1047248A1 (en) 2003-02-14
AU2005209600B2 (en) 2008-08-07
PL201878B1 (pl) 2009-05-29
HK1082433A1 (en) 2006-06-09
DE60113809T2 (de) 2006-06-22
KR20070051956A (ko) 2007-05-18
YU54602A (sh) 2006-01-16
JP5128743B2 (ja) 2013-01-23
RS52149B (sr) 2012-08-31
ATE305789T1 (de) 2005-10-15
MEP38008A (en) 2011-02-10
NZ520630A (en) 2004-09-24
PT1611892E (pt) 2009-11-20
CA2394165A1 (en) 2001-07-26
KR100913910B1 (ko) 2009-08-26
EP1257280A1 (en) 2002-11-20
ZA200206551B (en) 2006-04-29
SK287719B6 (en) 2011-07-06
ME00292B (me) 2011-05-10
EP1611892A3 (en) 2006-02-01
EP1611892A2 (en) 2006-01-04
RU2402331C2 (ru) 2010-10-27
EE200200401A (et) 2003-10-15
CA2394165C (en) 2010-04-13
ZA200601285B (en) 2008-01-08
IL150775A (en) 2008-08-07
NO335570B1 (no) 2014-12-29
RU2275198C2 (ru) 2006-04-27
SI1611892T1 (sl) 2010-01-29
WO2001052857A1 (en) 2001-07-26
KR20020088066A (ko) 2002-11-25
AU2005209600A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
IL191131A0 (en) Drospirenone for hormone replacement therapy
EP1598069A3 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
HU9602056D0 (en) Novel pharmaceutical composition containing phenofibrate
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
MY121397A (en) Ziprasidone formulations
AP2000001929A0 (en) Substituted indolealkanoic acids.
GB2364641A (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
IL139320A0 (en) Pharmaceutical compositions containing human parathyroid hormone
IL105468A0 (en) Pharmaceutical compositions for rectal administration
AU2624499A (en) Oral compositions at low dosage of cytotoxic proteins
MXPA02012957A (es) Formulacion nueva.
HUP0203655A2 (hu) Telítetlen 14,15-ciklopropano-androsztánok, előállításukat szolgáló eljárás és ezen vegyületeket tartalmazó gyógyszerészeti készítmények
Ivashin et al. Development of addiction to carbophos in the offspring of rats at administration during pregnancy.
WO2005041976A3 (en) Injectable gabapentin compositions